Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-06-14
2011-06-14
Huff, Sheela J (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S133100
Reexamination Certificate
active
07959923
ABSTRACT:
This invention relates to methods of inhibiting the growth of cells, in particular cancer cells, that overexpress Wnt2. The methods comprise contacting the cell with an agent that binds to Wnt2 mRNA or Wnt2 protein, interferes with Wnt2 signaling or inhibits binding of the Wnt2 protein to another protein, such as a Frizzled receptor.
REFERENCES:
patent: 5851984 (1998-12-01), Matthews et al.
patent: 6159462 (2000-12-01), Matthews et al.
patent: 6844422 (2005-01-01), Niehrs et al.
patent: 2002/0049177 (2002-04-01), Clark et al.
patent: 2002/0187502 (2002-12-01), Waterman et al.
patent: 2002/0192216 (2002-12-01), Lamb et al.
patent: 2003/0044408 (2003-03-01), Levy et al.
patent: 2003/0165500 (2003-09-01), Rhee et al.
patent: 2004/0126359 (2004-07-01), Lamb et al.
patent: 2004/0203003 (2004-10-01), Rhee et al.
patent: 2004/0223952 (2004-11-01), Ten Have-Opbroek
patent: 2004/0247593 (2004-12-01), He
patent: 2005/0049195 (2005-03-01), Zou
patent: 2005/0079173 (2005-04-01), Niehrs
patent: 2006/0040883 (2006-02-01), You et al.
patent: W09806747 (1998-02-01), None
patent: WO02088081 (2002-11-01), None
patent: 2004032838 (2004-04-01), None
patent: WO2004026908 (2004-04-01), None
patent: WO2004042028 (2004-05-01), None
Santa Cruz Biotechnology, Inc., Wnt-2 (V-16): sc-5207, http://www.scbt.com/datasheet-5207-wnt-2-v-16-antibody.html.Feb. 1995.
Santa Cruz Biotechnology, Inc., Wnt-2 (H-20): sc-5208, http://www.scbt.com/datasheet-5208-wnt-2-h-20-antibody.html.Feb. 1995.
Santa Cruz Biotechnology, Inc., Wnt-1 (G-19): sc-6280, http://www.scbt.com/datasheet-6280-wnt-1-g-19-antibody.html. Mar. 1998.
Elbashir, et al., Analysis of gene function in somatic mammalian cells using small interfering RNAs., Methods. Feb. 2002;26(2):199-213.
Appel, et al., Elucidation of discontinuous linear determinants in peptides, The Journal of Immunology, vol. 144, Issue 3 976-983, Copyright 1990 by American Association of Immunologists.
Bafico, et al.,Interaction of Frizzled Related Protein (FRP) with Wnt Ligands and the Frizzled Receptor Suggests Alternative Mechanisms for FRP Inhibition of Wnt Signaling, J Biol Chem, vol. 274, Issue 23, 16180-16187, Jun. 4, 1999.
Holcombe, et at., Expression of Wnt ligands and Frizzled receptors in colonic mucosa and in colon carcinoma, Molecular Pathology 2002;55:220-226.
Katoh, Frequent up-regulation of WNT2 in primary gastric cancer and colorectal cancer, Int J Oncol. Nov. 2001;19(5):1003-1007.
Levay-Young, et al., Growth and developmental regulation of wnt-2 (irp) gene in mesenchymal cells of fetal lung, AJP—Lung Cellular and Molecular Physiology, vol. 262, Issue 6 672-L683, (1992).
Li, et al., Second cysteine-rich domain of Dickkopf-2 activates Canonical Wnt signaling pathway via LRP-6 independently of dishevelled, The Journal of biological chemistry, 2002, vol. 277, No. 8, pp. 5977-5981.
Mahato, et al., Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA, Expert Opin Drug Deliv. Jan. 2005;2(1):3-28.
Molecular Biology, Proceedings of the 92nd Annual Meeting of the American Association for Cancer Research; Mar. 24-28, 2001; New Orleans, Lousianna, vol. 42, p. 609.
Sakurai, cDNA Macroarray Analysis of Genes Involved in the Progression of Human Non-small Cell Lung Carcinomas, Journal of Kanazawa Medical University, vol. 26;No. 4;p. 259-269(2001).
Scherer, et al., Approaches for the sequence-specific knockdown of mRNA, 2003, Nature Biotechnology 21(12), pp. 1457-1465.
Wissmann, et al., WIFI, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer, J. Pathol. 201, 2003, pp. 204-212.
Zhang, et al., Targeted gene silencing by small interfering RNA-based knock-down technology, Curr Pharm Biotechnol. Feb. 2004;5(1):1-7.
Chen, et al., Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription, The Journal of cell biology, vol. 152, No. 1. (Jan. 8, 2001), pp. 87-96.
He, et al., Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations, Oncogene. Apr. 21, 2005:24(18), pp. 1-5.
Lustig, et al., The Wnt signaling pathway and its role in tumor development, J Cancer Res Clin Oncol. Apr. 2003;129(4):199-221.
Polakis, Paul, Wnt signaling and cancer, Genes Dev. Aug. 1, 2000;14(15):1837-51.
Rhee, et al., Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas, Oncogene. Sep. 26, 2002;21(43):6598-6605.
You, et al., Wnt signaling promotes oncogenic transformation by inhibiting c-Myc—induced apoptosis, J. Cell Biol. 157(3): 429-440, (2002).
You, et al., Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells, Oncogene (2004) 23, 6170-6174.
You, et al., An Anti-Wnt-2 Monoclonal Antibody Induces Apoptosis in Malignant Melanoma Cells and Inhibits Tumor Growth, Cancer Research 64, 5385-5389, Aug. 1, 2004.
He Biao
Jablons David M.
Xu Zhidong
You Liang
Bozicevic Field & Francis LLP
Francis Carol L.
Huff Sheela J
The Regents of the University of California
LandOfFree
Method for treating cancer using anti-Wnt2 monoclonal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating cancer using anti-Wnt2 monoclonal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating cancer using anti-Wnt2 monoclonal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2661882